Sinovac Biotech Free Cash Flow (FCF) History (SVA)

Sinovac Biotech reported −$561.1M in free cash flow for fiscal 2025, a decrease of $408.3M from the previous fiscal year, with a free cash flow margin of −145.36%.

View full Sinovac Biotech company overview

Sinovac Biotech free cash flow by year

Sinovac Biotech annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$561.1M−$408.3M−145.36%
20242024-12-31−$152.9M−$135.3M−42.30%
20232023-12-31−$17.5M$1.09B−3.73%
20222022-12-31−$1.11B−$15.84B−75.47%
20212021-12-31$14.73B$14.38B+4086.11%+76.05%
20202020-12-31$351.8M$323.4M+1136.81%+68.90%
20192019-12-31$28.4M$26.1M+1120.86%+11.56%
20182018-12-31$2.3M−$45.5M−95.13%+1.01%
20172017-12-31$47.8M$74.4M+27.44%
20162016-12-31−$26.6M−$25.5M−36.66%
20152015-12-31−$1.1M$20.0M
20142014-12-31−$21.0M−$21.5M
20132013-12-31$443,000$32.9M
20122012-12-31−$32.4M−$30.9M
20112011-12-31−$1.5M$37.6M−2.68%
20102010-12-31−$39.1M−$83.2M−117.05%
20092009-12-31$44.1M+52.37%

Sinovac Biotech free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from $351.8M to −$561.1M, a net decrease of $912.9M.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Sinovac Biotech filings at SEC.gov ↗